The clinical implication of changing unbound quinidine levels

Kenneth M. Kessler, Paula M. Wozniak, Daneil McAuliffe, Elizabeth Terracall, Patricia Kozlovskis, Imrana Mahmood, Liaqat Zaman, Richard G. Trohman, Agustin Castellanos, Robert J Myerburg

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Pharmacodynamic and pharmacokinetic aspects pertinent to the potential clinical application of unbound quinidine levels were studied. Following heparin administration during electrophysiologic testing in 10 patients receiving quinidine, there were significant increases in the mean (± SD) right ventricular effective refractory period (266 ± 24 versus 279 ± 23; p < 0.025), free fatty acid concentration (515 ± 213 versus 1071 ± 359 mmol/L; p < 0.001), and unbound quinidine concentration (0.3 ± 0.1 to 0.6 ± 0.1 μg/ml; p < 0.001) but no changes in heart rate, corrected QT interval, or total plasma quinidine concentration. Ten control patients showed no change in the right ventricular effective refractory period following heparin administration. These findings were consistent with a heparin-induced increase in unbound drug concentration and activity that was limited to the vascular compartment. Eleven patients studied on day 3 (±1) and day 10 (±3) during an acute myocardial infarction showed a significant decrease in unbound quinidine fraction (12 ± 4% versus 9 ± 4%; p < 0.02) accompanied by a decrease, rather than the predicted increase, in half-life (7.1 ± 2.7 versus 6.3 ± 2.1 hours; p < 0.02). Volumes of distribution remained stable while the mean quinidine clearance tended to increase. Half-life correlated with albumin changes (r = -0.71; p < 0.02). Apparently, improvement in clinical status (assumed) and drug clearance (measured) negated the direct effects of the decrease in unbound quinidine fraction. Although unbound drug concentrations should correlate best with drug dynamic and kinetic information, full knowledge of the clinical context of such measurements is needed for appropriate interpretation.

Original languageEnglish
Pages (from-to)63-69
Number of pages7
JournalAmerican Heart Journal
Volume118
Issue number1
DOIs
StatePublished - Jan 1 1989

Fingerprint

Quinidine
Heparin
Half-Life
Pharmacokinetics
Pharmaceutical Preparations
Nonesterified Fatty Acids
Blood Vessels
Albumins
Heart Rate
Myocardial Infarction

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Kessler, K. M., Wozniak, P. M., McAuliffe, D., Terracall, E., Kozlovskis, P., Mahmood, I., ... Myerburg, R. J. (1989). The clinical implication of changing unbound quinidine levels. American Heart Journal, 118(1), 63-69. https://doi.org/10.1016/0002-8703(89)90073-2

The clinical implication of changing unbound quinidine levels. / Kessler, Kenneth M.; Wozniak, Paula M.; McAuliffe, Daneil; Terracall, Elizabeth; Kozlovskis, Patricia; Mahmood, Imrana; Zaman, Liaqat; Trohman, Richard G.; Castellanos, Agustin; Myerburg, Robert J.

In: American Heart Journal, Vol. 118, No. 1, 01.01.1989, p. 63-69.

Research output: Contribution to journalArticle

Kessler, KM, Wozniak, PM, McAuliffe, D, Terracall, E, Kozlovskis, P, Mahmood, I, Zaman, L, Trohman, RG, Castellanos, A & Myerburg, RJ 1989, 'The clinical implication of changing unbound quinidine levels', American Heart Journal, vol. 118, no. 1, pp. 63-69. https://doi.org/10.1016/0002-8703(89)90073-2
Kessler KM, Wozniak PM, McAuliffe D, Terracall E, Kozlovskis P, Mahmood I et al. The clinical implication of changing unbound quinidine levels. American Heart Journal. 1989 Jan 1;118(1):63-69. https://doi.org/10.1016/0002-8703(89)90073-2
Kessler, Kenneth M. ; Wozniak, Paula M. ; McAuliffe, Daneil ; Terracall, Elizabeth ; Kozlovskis, Patricia ; Mahmood, Imrana ; Zaman, Liaqat ; Trohman, Richard G. ; Castellanos, Agustin ; Myerburg, Robert J. / The clinical implication of changing unbound quinidine levels. In: American Heart Journal. 1989 ; Vol. 118, No. 1. pp. 63-69.
@article{cec4443bbea4428b958ee62df0ded756,
title = "The clinical implication of changing unbound quinidine levels",
abstract = "Pharmacodynamic and pharmacokinetic aspects pertinent to the potential clinical application of unbound quinidine levels were studied. Following heparin administration during electrophysiologic testing in 10 patients receiving quinidine, there were significant increases in the mean (± SD) right ventricular effective refractory period (266 ± 24 versus 279 ± 23; p < 0.025), free fatty acid concentration (515 ± 213 versus 1071 ± 359 mmol/L; p < 0.001), and unbound quinidine concentration (0.3 ± 0.1 to 0.6 ± 0.1 μg/ml; p < 0.001) but no changes in heart rate, corrected QT interval, or total plasma quinidine concentration. Ten control patients showed no change in the right ventricular effective refractory period following heparin administration. These findings were consistent with a heparin-induced increase in unbound drug concentration and activity that was limited to the vascular compartment. Eleven patients studied on day 3 (±1) and day 10 (±3) during an acute myocardial infarction showed a significant decrease in unbound quinidine fraction (12 ± 4{\%} versus 9 ± 4{\%}; p < 0.02) accompanied by a decrease, rather than the predicted increase, in half-life (7.1 ± 2.7 versus 6.3 ± 2.1 hours; p < 0.02). Volumes of distribution remained stable while the mean quinidine clearance tended to increase. Half-life correlated with albumin changes (r = -0.71; p < 0.02). Apparently, improvement in clinical status (assumed) and drug clearance (measured) negated the direct effects of the decrease in unbound quinidine fraction. Although unbound drug concentrations should correlate best with drug dynamic and kinetic information, full knowledge of the clinical context of such measurements is needed for appropriate interpretation.",
author = "Kessler, {Kenneth M.} and Wozniak, {Paula M.} and Daneil McAuliffe and Elizabeth Terracall and Patricia Kozlovskis and Imrana Mahmood and Liaqat Zaman and Trohman, {Richard G.} and Agustin Castellanos and Myerburg, {Robert J}",
year = "1989",
month = "1",
day = "1",
doi = "10.1016/0002-8703(89)90073-2",
language = "English",
volume = "118",
pages = "63--69",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - The clinical implication of changing unbound quinidine levels

AU - Kessler, Kenneth M.

AU - Wozniak, Paula M.

AU - McAuliffe, Daneil

AU - Terracall, Elizabeth

AU - Kozlovskis, Patricia

AU - Mahmood, Imrana

AU - Zaman, Liaqat

AU - Trohman, Richard G.

AU - Castellanos, Agustin

AU - Myerburg, Robert J

PY - 1989/1/1

Y1 - 1989/1/1

N2 - Pharmacodynamic and pharmacokinetic aspects pertinent to the potential clinical application of unbound quinidine levels were studied. Following heparin administration during electrophysiologic testing in 10 patients receiving quinidine, there were significant increases in the mean (± SD) right ventricular effective refractory period (266 ± 24 versus 279 ± 23; p < 0.025), free fatty acid concentration (515 ± 213 versus 1071 ± 359 mmol/L; p < 0.001), and unbound quinidine concentration (0.3 ± 0.1 to 0.6 ± 0.1 μg/ml; p < 0.001) but no changes in heart rate, corrected QT interval, or total plasma quinidine concentration. Ten control patients showed no change in the right ventricular effective refractory period following heparin administration. These findings were consistent with a heparin-induced increase in unbound drug concentration and activity that was limited to the vascular compartment. Eleven patients studied on day 3 (±1) and day 10 (±3) during an acute myocardial infarction showed a significant decrease in unbound quinidine fraction (12 ± 4% versus 9 ± 4%; p < 0.02) accompanied by a decrease, rather than the predicted increase, in half-life (7.1 ± 2.7 versus 6.3 ± 2.1 hours; p < 0.02). Volumes of distribution remained stable while the mean quinidine clearance tended to increase. Half-life correlated with albumin changes (r = -0.71; p < 0.02). Apparently, improvement in clinical status (assumed) and drug clearance (measured) negated the direct effects of the decrease in unbound quinidine fraction. Although unbound drug concentrations should correlate best with drug dynamic and kinetic information, full knowledge of the clinical context of such measurements is needed for appropriate interpretation.

AB - Pharmacodynamic and pharmacokinetic aspects pertinent to the potential clinical application of unbound quinidine levels were studied. Following heparin administration during electrophysiologic testing in 10 patients receiving quinidine, there were significant increases in the mean (± SD) right ventricular effective refractory period (266 ± 24 versus 279 ± 23; p < 0.025), free fatty acid concentration (515 ± 213 versus 1071 ± 359 mmol/L; p < 0.001), and unbound quinidine concentration (0.3 ± 0.1 to 0.6 ± 0.1 μg/ml; p < 0.001) but no changes in heart rate, corrected QT interval, or total plasma quinidine concentration. Ten control patients showed no change in the right ventricular effective refractory period following heparin administration. These findings were consistent with a heparin-induced increase in unbound drug concentration and activity that was limited to the vascular compartment. Eleven patients studied on day 3 (±1) and day 10 (±3) during an acute myocardial infarction showed a significant decrease in unbound quinidine fraction (12 ± 4% versus 9 ± 4%; p < 0.02) accompanied by a decrease, rather than the predicted increase, in half-life (7.1 ± 2.7 versus 6.3 ± 2.1 hours; p < 0.02). Volumes of distribution remained stable while the mean quinidine clearance tended to increase. Half-life correlated with albumin changes (r = -0.71; p < 0.02). Apparently, improvement in clinical status (assumed) and drug clearance (measured) negated the direct effects of the decrease in unbound quinidine fraction. Although unbound drug concentrations should correlate best with drug dynamic and kinetic information, full knowledge of the clinical context of such measurements is needed for appropriate interpretation.

UR - http://www.scopus.com/inward/record.url?scp=0024324788&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024324788&partnerID=8YFLogxK

U2 - 10.1016/0002-8703(89)90073-2

DO - 10.1016/0002-8703(89)90073-2

M3 - Article

VL - 118

SP - 63

EP - 69

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 1

ER -